Affordability can be an issue with the higher priced long-acting insulin analogues in Bangladesh, with Shariful Islam et al. (129) documenting that patients with diabetes paid an average of 35,385 BDT (US$454) per year for their medicines vs. only 1609 BDT (US$21) for those patients without diabetes. This evidence concerns the gene INS and diabetes mellitus.